PERTH, AUSTRALIA: 25 November 2013 – Leading peptide drug discovery company Phylogica Ltd (ASX:PYC, XETRA:PH7) provides the following update in relation to the Recapitalisation announcements made on 11 and 18 November 2013.
Rights Issue
As previously foreshadowed, the Company has made a submission to the Australian Securities and Investments Commission (“ASIC”) for approval of the appointment of a broker to handle the sale of securities owned by overseas shareholders.
The commencement date of the Rights Issue will be determined by the timing of the ASIC response to that submission.
For further information please download PDF below:
